NEWS
Attruby™ (acoramidis), a Near Complete TTR Stabilizer (≥90%), approved by FDA to Reduce Cardiovascular Death and Cardiovascular-related Hospitalization in ATTR-CM Patients
BridgeBio Pharma announced FDA approval of Attruby™ (acoramidis) for treating adults with ATTR-CM to reduce cardiovascular death and hospitalization.
The approval is based on the ATTRibute-CM Phase 3 study results, showing a 42% reduction in composite all-cause mortality and recurrent cardiovascular-related hospitalizations at Month 30.
Attruby demonstrated rapid benefits within 3 months and achieved a 50% reduction in cardiovascular-related hospitalization events.
As the first approved product with near-complete TTR stabilization (≥90%), Attruby preserves native TTR function.
BridgeBio will receive a $500 million payment under their royalty funding agreement and has submitted for European approval, expected in 2025.
Grants Bayer Rights to Commercialize Acoramidis in Europe
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
2598Followers
107Following
28KVisitors
Follow